• Latest
  • Trending
  • All
  • Transplant
  • Dialysis
  • Donation
Atara Biotherapeutics: Still Bullish On Long-Term Prospects (NASDAQ:ATRA)

Atara Biotherapeutics: Still Bullish On Long-Term Prospects (NASDAQ:ATRA)

Norwalk Teen Receives ‘Second Chance at Life’ With Heart Transplant on Christmas Eve – myfox8.com

Norwalk Teen Receives ‘Second Chance at Life’ With Heart Transplant on Christmas Eve – myfox8.com

Nephros Provides Year-End Technology Update, Including HDF Program Status

XORTX Provides Corporate Update | BioSpace

Key Changes to the Anti-Kickback Statute and Civil Monetary Penalty Rules | Hodgson Russ LLP

Key Changes to the Anti-Kickback Statute and Civil Monetary Penalty Rules | Hodgson Russ LLP

Study exploring the impact of cannabis on liver transplant outcomes found there weren’t any

Study exploring the impact of cannabis on liver transplant outcomes found there weren’t any

Norwich’s Hutchinson targets return after kidney transplant

Norwich’s Hutchinson targets return after kidney transplant

Kidney Dialysis Equipment Market Research Report And Predictive Business Strategy By 2027

Kidney Dialysis Equipment Market Research Report And Predictive Business Strategy By 2027

Nation’s Top Liver Transplant Program at Rutgers-Affiliated University Hospital

Nation’s Top Liver Transplant Program at Rutgers-Affiliated University Hospital

XORTX Announces Grant of European Patent Canadian Stock Exchange:XRX.CN

XORTX Provides Corporate Update Canadian Stock Exchange:XRX.CN

TONI KING: Stress changing Medicare plan

TONI KING: Stress changing Medicare plan

Tower Completes Successful Liver Transplant Surgery

Tower Completes Successful Liver Transplant Surgery

Trending News Corona impact on Kidney Transplant Rejection Therapeutics Market Growth Analysis and Forecast Including Factors, Development, Trends Up To 2027

Trending News Corona impact on Kidney Transplant Rejection Therapeutics Market Growth Analysis and Forecast Including Factors, Development, Trends Up To 2027

Peritoneal Dialysis Machines Market To Attain A Valuation of Highest CAGR 2020-2027 – NeighborWebSJ

Peritoneal Dialysis Machines Market To Attain A Valuation of Highest CAGR 2020-2027 – NeighborWebSJ

  • Privacy Policy
  • Terms and Conditions
  • About Us
  • Contact Us
Wednesday, January 20, 2021
Transplant News
No Result
View All Result
  • Home
  • Transplant
    • All
    • Kidney Transplant
    Norwalk Teen Receives ‘Second Chance at Life’ With Heart Transplant on Christmas Eve – myfox8.com

    Norwalk Teen Receives ‘Second Chance at Life’ With Heart Transplant on Christmas Eve – myfox8.com

    Nephros Provides Year-End Technology Update, Including HDF Program Status

    XORTX Provides Corporate Update | BioSpace

    Study exploring the impact of cannabis on liver transplant outcomes found there weren’t any

    Study exploring the impact of cannabis on liver transplant outcomes found there weren’t any

    Norwich’s Hutchinson targets return after kidney transplant

    Norwich’s Hutchinson targets return after kidney transplant

    Nation’s Top Liver Transplant Program at Rutgers-Affiliated University Hospital

    Nation’s Top Liver Transplant Program at Rutgers-Affiliated University Hospital

    XORTX Announces Grant of European Patent Canadian Stock Exchange:XRX.CN

    XORTX Provides Corporate Update Canadian Stock Exchange:XRX.CN

    Tower Completes Successful Liver Transplant Surgery

    Tower Completes Successful Liver Transplant Surgery

    Trending News Corona impact on Kidney Transplant Rejection Therapeutics Market Growth Analysis and Forecast Including Factors, Development, Trends Up To 2027

    Trending News Corona impact on Kidney Transplant Rejection Therapeutics Market Growth Analysis and Forecast Including Factors, Development, Trends Up To 2027

    An ethical analysis of obesity as a determinant of pediatric heart transplant candidacy

    Robot-Assisted Radical Prostatectomy in a Second Kidney Transplant Recipient

    Suspending kidney transplants will ‘see organs wasted’, says Shropshire man

    Suspending kidney transplants will ‘see organs wasted’, says Shropshire man

  • Donation
    • All
    • Kidney Donation
    • Liver Donation
    • Organ Donation
    Study Finds Cannabis May Not Negatively Impact Liver Transplant Patients

    Study Finds Cannabis May Not Negatively Impact Liver Transplant Patients

    Parents donate organs of brain dead 20-year-old girl under organ donation initiative Jeevandan- Edexlive

    Parents donate organs of brain dead 20-year-old girl under organ donation initiative Jeevandan- Edexlive

    Ultra-low Temperature Freezers Market revenue to cross USD 600 Mn by 2026: Global Market Insights, Inc.

    Ultra-low Temperature Freezers Market revenue to cross USD 600 Mn by 2026: Global Market Insights, Inc.

    Students push to change organ donor registry in hopes of saving more lives

    Students push to change organ donor registry in hopes of saving more lives | WWTI

    New Hampshire man receives life-saving organ transplant at UW Health

    New Hampshire man receives life-saving organ transplant at UW Health

    For Second Consecutive Year, CORE Breaks Organ Donation Record | News

    For Second Consecutive Year, CORE Breaks Organ Donation Record | News

    Joey Gase back with Rick Ware Racing for 2021

    Joey Gase back with Rick Ware Racing for 2021

    Dialysis Market Latest Research Forecast 2020-2029 | Top Players: Fresenius Medical Care AG & Co KGaA, Baxter International Inc, DaVita Inc

    Regenerative Therapies Market Size to Expand at Highest Revenue US$ 45,940.7 Million by 2027, Owing to Rapid Growth of Stem Cell Businesses

    Highland politician Edward Mountain in plea for transplant patients to be prioritised for Covid-19 vaccine

    Highland politician Edward Mountain in plea for transplant patients to be prioritised for Covid-19 vaccine

    MTF Biologics Awards Over $1 Million in 2020 Extramural Research Grants and Announces Timeline for 2021 Applications

    MTF Biologics Awards Over $1 Million in 2020 Extramural Research Grants and Announces Timeline for 2021 Applications

  • Dialysis
    Key Changes to the Anti-Kickback Statute and Civil Monetary Penalty Rules | Hodgson Russ LLP

    Key Changes to the Anti-Kickback Statute and Civil Monetary Penalty Rules | Hodgson Russ LLP

    Kidney Dialysis Equipment Market Research Report And Predictive Business Strategy By 2027

    Kidney Dialysis Equipment Market Research Report And Predictive Business Strategy By 2027

    TONI KING: Stress changing Medicare plan

    TONI KING: Stress changing Medicare plan

    Peritoneal Dialysis Machines Market To Attain A Valuation of Highest CAGR 2020-2027 – NeighborWebSJ

    Peritoneal Dialysis Machines Market To Attain A Valuation of Highest CAGR 2020-2027 – NeighborWebSJ

    Impact Of Covid-19 On Peritoneal Dialysis Solutions Market 2020: Remarking Enormous Growth With Recent Trends

    Dialysis Disposable Devices Market 2020

    Dialysis Equipment Market Size By Analysis, Key Vendors, Regions, Type and Application, and Forecasts to 2027 – NeighborWebSJ

    Peritoneal Dialysis Product Market Size By Analysis, Key Vendors, Regions, Type and Application, and Forecasts to 2027 – NeighborWebSJ

    Dialysis Equipment Market Size By Analysis, Key Vendors, Regions, Type and Application, and Forecasts to 2027 – NeighborWebSJ

    Portable and Wearable Dialysis Devices Market Size By Analysis, Key Vendors, Regions, Type and Application, and Forecasts to 2027 – NeighborWebSJ

    PERITONEAL DIALYSIS PRODUCT Market Repository of Analysis, Information for Every Facet of the Industry – NeighborWebSJ

    PERITONEAL DIALYSIS PRODUCT Market Repository of Analysis, Information for Every Facet of the Industry – NeighborWebSJ

    Portable Dialysis Machines Market Globally Expected to Drive Growth through 2018-2026 – NeighborWebSJ

    Portable Dialysis Machines Market Globally Expected to Drive Growth through 2018-2026 – NeighborWebSJ

    Impact of Covid-19 on Dialysis Water Treatment Market Is Booming Worldwide |Fresenius Medical Care, Gambro, DWA, Lauer Membran Wassertechnik, etc. – KSU

    Impact of Covid-19 on Dialysis Water Treatment Market Is Booming Worldwide |Fresenius Medical Care, Gambro, DWA, Lauer Membran Wassertechnik, etc. – KSU

  • Donor
    • All
    • Kidney Donor
    • Organ Donor
    From a hospital staff to an organ transplant racketeer..

    From a hospital staff to an organ transplant racketeer..

    Here’s what you need to know this morning: Monday, Jan. 18 | Mid-Missouri News

    Here’s what you need to know this morning: Monday, Jan. 18 | Mid-Missouri News

    Litchfield mother desperate for kidney transplant searches for living donor

    Litchfield mother desperate for kidney transplant searches for living donor

    Odisha Governor Ganeshi Lal appeals for efficient use of fuel- The New Indian Express

    Odisha Governor Ganeshi Lal appeals for efficient use of fuel- The New Indian Express

    Himanshu’s Arrest May Open Pandora’s Box!

    Himanshu’s Arrest May Open Pandora’s Box!

    Cops to take conman on three-day remand- The New Indian Express

    Cops to take conman on three-day remand- The New Indian Express

    Students push to change organ donor registry in hopes of saving more lives

    Change organ donor registry to save more lives, students say

    Type mismatch made for TV

    Type mismatch made for TV

    Battery of charges against conman over kidney donors fraud- The New Indian Express

    Battery of charges against conman over kidney donors fraud- The New Indian Express

    Aubree Burton, 16, seeks kidney donor – Dorchester Banner

    Aubree Burton, 16, seeks kidney donor – Dorchester Banner

  • Editor’s Pick
  • Videos
    Exercise and Lifestyle with Cardiomyopathy

    Exercise and Lifestyle with Cardiomyopathy

    BSC Renal Dialysis Technology Course career and scope in malayalam

    BSC Renal Dialysis Technology Course career and scope in malayalam

    On the other side, my experience as a stem cell donor

    On the other side, my experience as a stem cell donor

    Rehman Free Dialysis Center

    Rehman Free Dialysis Center

    Advances in Lung Transplant: Better Testing, Matching and Conditioning

    Advances in Lung Transplant: Better Testing, Matching and Conditioning

    Dialysis time

    Dialysis time

    Medical Treatment of Dilated Cardiomyopathy – Chet Patel, MD

    Medical Treatment of Dilated Cardiomyopathy – Chet Patel, MD

    Vlog088 "My Mini Dialysis Testimony"

    Vlog088 "My Mini Dialysis Testimony"

    MacLean Conference – Walter Glannon "Are We Underestimating the Risk in Living Kidney Donation?"

    MacLean Conference – Walter Glannon "Are We Underestimating the Risk in Living Kidney Donation?"

Transplant News
Home Transplant

Atara Biotherapeutics: Still Bullish On Long-Term Prospects (NASDAQ:ATRA)

in Transplant
Atara Biotherapeutics: Still Bullish On Long-Term Prospects (NASDAQ:ATRA)
491
SHARES
1.4k
VIEWS
Share on FacebookShare on Twitter

By writer to seekingalpha.com

Introduction

Since I first wrote about Atara Biotherapeutics (ATRA) in October 2019, its share value has gone by way of a rollercoaster journey, reflecting the binary nature of investing in clinical-stage biotech firms. Share costs went as excessive as much as over $17, earlier than dropping by over 50% following the inventory market crash as a consequence of uncertainty over the COVID-19 pandemic.

Since my first article, Atara’s new CEO, Pascal Touchon, has settled in nicely and refocused the corporate’s strategic priorities. On this article, I revisit its prospects and reaffirm my bullish views on the corporate.

Scientific Packages Updates

In its Q3 2019 earnings name in November 2019, Atara Biotherapeutics up to date that its strategic focus transferring ahead will probably be on its lead program, tab-cel, ATA 188 for a number of sclerosis (“MS”), ATA2271/3271 Mesothelin-targeted CAR-Ts for stable tumors, and ATA 3219 CD-19 focused CAR-T for B-cell malignancies. Determine 1 lists the corporate’s newest medical applications.

Determine 1: Atara Biotherapeutics’ Scientific Pipeline

A screenshot of a cell phone Description automatically generated

(Supply: Company Investor Presentation, February 27, 2020)

As a recap, the corporate’s lead program, tab-cel, is an allogeneic Epstein-Barr virus (“EBV”)-specific T-cell immunotherapy and is being evaluated in a part Three trial for EBV+ Publish-Transplant Lymphoproliferative Illness (“PTLD”) following bone marrow transplant (“HCT”) or stable organ transplant (“SOT”). PTLD is an aggressive and uncommon B-cell lymphoma that happens in immunosuppressed sufferers after transplant and is usually lethal and has no accredited remedy.

Determine 2: Tab-cel medical information for sufferers with EBV+ PTLD

A screenshot of a cell phone Description automatically generated

(Supply: Firm Investor Presentation, February 27, 2020)

Tab-cel has proven compelling leads to sufferers with EBV+ PTLD with wonderful goal response charges (“ORR”) reported for the part 2 trial and an ongoing expanded entry protocol (“EAP”). Following an preliminary slower-than-expected enrolment for the ultra-rare illness, Atara had up to date its steering that the submitting of a biologics license functions (“BLA”) will probably be initiated within the second half of 2020. With an anticipated main endpoint threshold of 37%, the present obtainable information for tab-cel have far exceeded the edge, and tab-cel must be the primary allogeneic T-cell immunotherapy to be accredited in any indication. Just lately, the corporate additionally announced enterprise updates concerning the COVID-19 pandemic and confirmed that the timeline for BLA submission of tab-cel would probably not be affected.

Determine 3: Industrial Alternative for Tab-cel

A screenshot of a social media post Description automatically generated

(Supply: Firm Investor Presentation, February 27, 2020)

Moreover, the corporate additionally expects that the slower-than-expected enrolment of tab-cel within the pivotal trial doesn’t mirror the industrial alternative if approval is granted. Because the product is off-the-shelf allogenic, the supply to sufferers may be achieved rapidly and to any transplant middle in comparison with the present medical trial websites, which solely cowl round 10% of US transplant facilities. Assuming approval, physicians can even probably favor the usage of an accredited product fairly than the present state of affairs the place there are competing medical trials with tab-cel. The corporate can also be working a part 2 trial for Nasopharyngeal carcinoma (“NPC”) and plans to begin a part 2 trial within the second half of the 12 months to judge tab-cel in different uncommon EBV+ most cancers. The addition of indications will additional broaden the goal inhabitants that may be handled with tab-cel.

Transferring on to ATA188 for the remedy of MS, the preliminary plan was to dose Four ranges and choose the optimum dose stage. Atara had determined to go forward with dose stage Three for the part 1b research based mostly on a well-tolerated security profile and demonstrated medical enchancment from this dose stage. The corporate had earlier reported interim information for the primary 2-dose stage, and ATA 188 was well-tolerated in sufferers with progressive types of MS with no proof of cytokine launch syndrome, graft versus host illness or dose-limiting toxicities. The part 1b trial was initially anticipated to be initiated in Q2 or Q3 this 12 months, however the firm had introduced that it was suspending enrolment of ATA188 because of the COVID-19 pandemic. Whereas it’s unclear on the total affect on the timeline of the trial, the corporate nonetheless expects to report interim information updates from dose ranges Three and Four of the part 1 trial at an acceptable discussion board.

The corporate’s final two strategic priorities are each specializing in CAR-Ts. Atara’s collaborator, Memorial Sloan Kettering (“MSK”), is predicted to submit an IND within the 2nd or 3rd quarter of 2020 for ATA2271, which is an autologous mesothelin focused CAR-T in sufferers with superior mesothelioma. ATA 2271 incorporates next-generation applied sciences, together with novel co-stimulatory area 1XX which will supply higher persistence and extra physiologic T-cell signaling in addition to a PD-1 dominant unfavourable receptor that’s designed to supply intrinsic checkpoint inhibition and unlock the stable tumor microenvironment.

Moreover, an instructional just lately presented a medical proof-of-principle that an EBV T-cell platform has the potential to generate allogeneic CAR-Ts with excessive and sturdy responses, in addition to a low threat of toxicity. Within the EBV CD-19 CAR-T research, 5 out of 6 sufferers have been noticed to have sturdy full responses, with a median follow-up of 26.9 months. Based mostly on this, the corporate has began preclinical IND enabling research for ATA3219, which is an allogeneic EBV CD-19 focused CAR-T that comes with 1XX.

Determine 4: Atara Biotherapeutics’ CAR-T Developments

A close up of a map Description automatically generated

(Supply: Firm Investor Presentation, February 27, 2020)

Lastly, the corporate has additionally began preclinical IND enabling research for ATA3271, which is the allogeneic model of ATA 2271 and incorporates findings from each ATA2271 and ATA 3219.

Prospects

As of December 31, 2019, money and equivalents available have been $259.1 million, which the corporate expects to fund operations into the second quarter of 2020. Given the comparatively brief money runway, I’d count on the corporate to lift additional cash on the subsequent occasion of a optimistic catalyst, which might be probably the initiation of a BLA submission for tab-cel. Whereas buyers could be happy to listen to that there aren’t any anticipated additional delays to the BLA submission of tab-cel, the enrolment of ATA188 has been suspended. It’s also unclear if there will probably be any delays to ATA2271, which will probably be carried out by MSK and never Atara. A number of medical trials have already been delayed globally, and it’s unclear if this may any affect on the corporate’s money burn.

As an allogeneic immunotherapy firm that’s increasingly focusing on CAR-T, Atara competes with a number of firms, notably these which can be creating allogeneic CAR-Ts. Such firms embrace Cellectis (CLLS), Allogene Therapeutics (ALLO), Precision BioSciences (DTIL) and CRISPR Therapeutics (CRSP). The primary distinction amongst these firms is primarily the selection of gene-editing instruments. Cellectis is each Allogene’s accomplice and competitor, and each use TALEN, whereas Precision is utilizing ARCUS and CRISPR is utilizing its namesake CRISPR/Cas9 for gene enhancing. All these firms are in an identical stage of medical improvement in allogeneic CAR-T, with a number of applications deliberate in early-stage trials.

Determine 5: Benefits of Atara Biotherapeutics’ Platform

A screenshot of a cell phone Description automatically generated

(Supply: Firm Investor Presentation, February 27, 2020)

Atara’s EBV-based platform has a number of benefits over the talked about firms’ applied sciences. Firstly, EBV is current within the majority of the inhabitants and is implicated in a variety of cancers and autoimmune ailments. There isn’t any want for gene enhancing for EBV T cells, which provides it a long-term persistence benefit and it might probably develop in sufferers with none lymphodepleting chemotherapy pre-treatment.

Past wholesome donors derived allogeneic therapies, firms comparable to Fate Therapeutics (FATE) are engaged on induced pluripotent stem cells (“IPSC”)-derived allogeneic therapeutics. By utilizing IPSCs as a renewable cell supply, there may be a number of benefits over wholesome donor-derived allogeneic therapies. Such benefits embrace improved product consistency and efficiency, and a producing course of that’s extra akin to the well-established biologics area the place they’re produced from a single cell line. Whereas the expertise is promising, the corporate focus seems to be extra on Pure Kill (“NK”) cells. In any case, Destiny’s medical trials are comparatively early stage in comparison with Atara, whose tab-cel is probably the most superior allogeneic T cell immunotherapy in medical improvement for any indication.

Conclusion

Regardless of share value dropping by round 50% since my first article, I stay extraordinarily bullish on Atara’s long-term prospects, because it has probably the most superior T cell immunotherapy in medical improvement for any indication and, for my part, is prone to obtain approval. Its EBV-based platform additionally holds a number of benefits over different CAR-T gamers, as mentioned above.

On the company entrance, the corporate appears to have stabilized for the reason that slower anticipated enrolment of tab-cel and the exodus of administration. Nonetheless, my preliminary hopes of Atara being purchased out seem to have gone away for the brief time period, with the corporate’s latest appointment of a chief industrial officer signaling its intent to self-commercialize tab-cel within the close to time period. Given the present circumstances, the corporate ought to focus its efforts on efficiently commercializing tab-cel to maximise shareholder worth.

Total, I stay bullish on Atara’s prospects and I nonetheless maintain a medium-sized place that’s within the purple at present, I’ve no intention of promoting them anytime quickly. I do, nevertheless, change my advice from “Very Bullish” to “Bullish” because of the latest market turmoil and the dearth of intention to enter new positions to common down, given the unlikelihood of a near-term buyout and the corporate’s comparatively brief money runway.

As all the time, buyers ought to conduct their very own due diligence and take into account their threat appetites and time horizon earlier than taking on any place. I specialize in protecting tech and biotech companies. Readers who’re are welcome to observe me to learn and touch upon my articles.

Disclosure: I’m/we’re lengthy ATRA. I wrote this text myself, and it expresses my very own opinions. I’m not receiving compensation for it (aside from from Searching for Alpha). I’ve no enterprise relationship with any firm whose inventory is talked about on this article.

— to seekingalpha.com

Share196Tweet123Share49
Previous Post

Kidney transplant celebration cut short by COVID-19

Next Post

Kidney donor urges others to ‘change a person’s life’

Next Post
Kidney donor urges others to ‘change a person’s life’

Kidney donor urges others to ‘change a person’s life’

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Editor's Pick

San Francisco police officer donates kidney to save a stranger
Editor's Pick

San Francisco police officer donates kidney to save a stranger

(CNN)San Francisco Police Officer Anna Cuthbertson hadn't considered organ donation until she listened to a podcast about a woman who...

Kidney donor surprises Long Island recipient with visit

Kidney donor surprises Long Island recipient with visit

Woman Who Underwent Historic Double Transplant Surgery To Get New Kidney

Woman Who Underwent Historic Double Transplant Surgery To Get New Kidney

Patriots’ Tom Brady on Mission to Help Mentor

More in need of organ transplants seek their own donors

More in need of organ transplants seek their own donors

New England Patriots Tom Brady Helps To Save The Life Of A Woman Needing A Lifesaving Kidney Transplant

New England Patriots Tom Brady Helps To Save The Life Of A Woman Needing A Lifesaving Kidney Transplant

Tom Brady Continues to do His Part in Saving Lives

Tom Brady Continues to do His Part in Saving Lives

People Turn Online To Find Organ Matches

People Turn Online To Find Organ Matches

Oahu woman gives priceless Thanksgiving gift

Oahu woman gives priceless Thanksgiving gift

Tom Brady honors mentor with donation to local organ transplant organization

Tom Brady honors mentor with donation to local organ transplant organization

Tom Brady Helps Lexington Mom Get New Kidney

Tom Brady Helps Lexington Mom Get New Kidney

Local family searching for a kidney donor

Local family searching for a kidney donor

Transplant News

Copyright © 2020 All rights reserved.

Navigate Site

  • Privacy Policy
  • Terms and Conditions
  • About Us
  • Contact Us

Follow Us

No Result
View All Result
  • Home
  • Transplant
    • Kidney Transplant
  • Donation
    • Kidney Donation
    • Liver Donation
    • Organ Donation
  • Dialysis
  • Donor
    • Kidney Donor
    • Organ Donor
  • Videos
  • Editor’s Pick

Copyright © 2020 All rights reserved.